商品编号


CHI-HR-20015-C050



品牌


Adipogen



公司


Adipogen



公司分类


Proteins



Size

50 ?g

商品信息


More Information



Product Details



Synonyms

Interleukin-15



Product Type

Protein



Properties



Source/Host

E. coli



Sequence

The extracellular domain of human IL-15 (aa 49-162) is fused to a His-tag.



Crossreactivity

Human



BIOLOG
ical Activity

Measured by its
ABI
lity to stimulate the proliferation of mouse CTLL-2 cells. The ED50 for this effect is typically 0.5ng/mL, corresponding to a specific activity of 2x 10
6
units/mg



MW

~14kDa (SDS-PAGE)



Purity

≥95% (SDS-PAGE)



Endotoxin Content

<0.1eu mu;g="" protein="" (lal="" test;="" lonza).="">0.1eu>



Reconstitution

Reconstitute 10?g vial with 100 ?l sterile water to a concentration of 0.1mg/ml.
Reconstitute 50?g vial with 100 ?l sterile water to a concentration of 0.5mg/ml.
Add 1X PBS to the desired protein concentration.



Formulation

Lyophilized from 0.2μm-filtered solution in PBS.



Other Product Data

NCBI reference NP_751914.1: IL-15 (human)



Declaration

Manufactured by Chimerigen.



Shipping and Handling



Shipping

BLUE ICE



Short Term Storage

+4°C



Long Term Storage

-20°C



Handling Advice

Avoid freeze/thaw cycles.
PBS containing at least 0.1% BSA should be used for further dilutions.



Use/St
ABI
lity

Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.



Documents



MSD
S

No



Product Specification Sheet



Datasheet


Download PDF





Interleukin-15 (IL-15) has a broad spectrum of
BIOLOG
ical activities. It is crucial for the development, proliferation, survival and differentiation of multiple cells from both innate and adaptive immune systems. IL-15 up-regulation has a central role in the development of several autoimmune or chronic inflammatory disorders. Targeting IL-15 or its receptor may have a valuable impact on the treatment of immune-mediated diseases. IL-15 participates in the development of important immune antitumor mechanisms. It activates CD8(+) T cells, natural killer (NK) cells, NK T cells, and can promote the formation of antitumor antibodies. IL-15 can also protect T effector cells from the action of T regulatory cells and reverse tolerance to tumor-associated antigens. In pre-clinical studies IL-15 has been found to demonstrate potentiated antitumor effects following pre-association with IL-15Rα, or when used in combination with chemotherapy, adoptive therapy, monoclonal antibodies, and tumor vaccines.